Today: 31 May 2026
BitMine (BMNR) stock barely budges after $5.2 billion quarterly loss as share-vote deadline nears
14 January 2026
1 min read

BitMine (BMNR) stock barely budges after $5.2 billion quarterly loss as share-vote deadline nears

New York, Jan 13, 2026, 21:27 EST — The market has closed.

  • BMNR closed Tuesday up 0.1% at $31.15 and was last seen trading at $31.22 after hours
  • The quarterly filing revealed a $5.2 billion net loss, driven largely by a significant unrealized loss on digital assets
  • Investors are zeroing in on the Jan. 14 voting deadline and the Jan. 15 annual meeting, where the plan to increase authorized shares will be up for a vote

Shares of BitMine Immersion Technologies Inc barely budged Tuesday, edging up roughly 0.2% after the market closed. The company reported a quarterly net loss of $5.2 billion, largely due to an unrealized loss on digital assets amounting to $5.25 billion. Revenue climbed 91% to $2.3 million. As of Nov. 30, the filing revealed digital assets valued at $10.6 billion, with cash and cash equivalents near $888 million.

The numbers are crucial since BitMine’s operating line is tiny compared to its crypto balance sheet. This shifts the stock’s narrative—and its risk—away from mining and squarely onto the daily fluctuations of digital tokens.

Unrealized losses reflect paper losses from marking holdings to market. They can bounce back if prices recover, but when crypto tanks, these losses can quickly balloon—and hit earnings hard.

The quarter highlights the key question for traders ahead of Wednesday’s session: can BitMine continue funding its crypto “treasury” strategy without diluting current shareholders too much?

BitMine’s latest 10-Q reveals a clear shift in its revenue mix, moving away from self-mining and leaning more on leasing, consulting, and staking. Staking involves locking up tokens to support blockchain operations, earning rewards in return.

Another factor coming up soon is a shareholder vote that could let the company issue more stock. Authorized shares represent the max a company can issue before needing shareholder OK. Tom Lee, BitMine’s chairman, said the company needs holders to pass Proposal No. 2 to raise authorized shares, noting that “when that happens, our ETH accumulation will slow.” He added the company’s charter demands approval from 50.1% of all outstanding shares to move forward.

BitMine highlighted its crypto assets ahead of its upcoming vote. The firm reported combined “crypto + total cash + ‘moonshots’” holdings of $14.0 billion as of Jan. 11. This includes roughly 4.17 million ether tokens, $988 million in cash, 193 bitcoin, plus an equity stake labeled as “moonshots.” The annual meeting is scheduled for Jan. 15 at Wynn Las Vegas, with proxy voting by phone and online closing at 11:59 p.m. ET on Jan. 14. PR Newswire

Crypto prices climbed approaching the U.S. close, adding another variable to watch. Ether gained roughly 7.5%, reaching $3,333.81.

The share vote looms large. Earlier proxy filings pitched Proposal 2 as a jump in authorized shares—from 500 million to 50 billion—a move that could stoke dilution worries if BitMine ramps up equity sales to fund more crypto purchases.

Investors will be eyeing any market response to Wednesday’s freshly filed 10-Q, then turning to the Jan. 14 vote cutoff and Jan. 15 meeting for a sharper sense of BitMine’s plans to ramp up its ether holdings.

Stock Market Today

  • Nanobiotix Raises €85 Million to Advance JNJ-1900 Cancer Treatment Amid Volatile Stock Rally
    May 30, 2026, 6:54 PM EDT. Nanobiotix (ENXTPA:NANO) completed a €85 million global equity raise to fund the development of JNJ-1900 (NBTXR3), a leading cancer treatment candidate. The financing follows promising Phase 2 trial results in inoperable non-small cell lung cancer, sponsored by Johnson & Johnson. Despite a recent 6.6% dip, shares have soared over 79% year-to-date, closing at €34.04, reflecting high market sensitivity to company developments. The fundraise attracted both European and U.S. investors through ordinary shares, American Depositary Shares, and pre-funded warrants issued near the current share price, suggesting robust demand without steep discounting. Investors will closely monitor Nanobiotix's clinical progress, regulatory updates, and potential partnerships, amid dilution concerns due to the new equity issue.

Latest articles

Realty Income Stock Dips Ahead of Jobs Data; Dividend Investors Eye Rates

Realty Income Stock Dips Ahead of Jobs Data; Dividend Investors Eye Rates

31 May 2026
Realty Income closed Friday at $61.28, down from $62.02 the previous week, as property stocks lagged broader market gains. The company declared a $0.2705 monthly dividend, payable June 15 to shareholders of record May 29. CEO Sumit Roy will present at Nareit’s REITweek on June 3. Investors await the U.S. May jobs report on June 5.
Oklo Stock Higher After Plutonium-Fuel Update

Oklo Stock Higher After Plutonium-Fuel Update

31 May 2026
Oklo shares closed at $66.88 Friday, down 1.78%, after a week of gains sparked by news the U.S. Department of Energy selected the company for advanced talks on using surplus plutonium as reactor fuel. Trading volume reached 27.67 million shares. Oklo reported a first-quarter net loss of $33.1 million and ended March with $2.54 billion in cash and equivalents.
Cameco Stock Is Back in Focus After a Mine Restart — What Investors Watch Next

Cameco Stock Is Back in Focus After a Mine Restart — What Investors Watch Next

31 May 2026
Cameco shares closed Friday at C$154.91 on the TSX, up 7.1% for the week after full production resumed at McArthur River and Key Lake following flood-related disruptions. The company kept its 2026 uranium output guidance unchanged at 19.5–21.5 million pounds. CIBC and National Bank of Canada maintained “Outperform” ratings. Cameco reported Q1 net earnings of C$131 million earlier in May.
Coca-Cola stock rises as KO sets Feb. 10 earnings date; what investors watch next
Previous Story

Coca-Cola stock rises as KO sets Feb. 10 earnings date; what investors watch next

NatWest share price edges up as buyback rolls on and board change lands ahead of Feb results
Next Story

NatWest share price edges up as buyback rolls on and board change lands ahead of Feb results

Go toTop